News

Overall Mortality in Cardiac Neonatal Lupus is 18%


 

Major Finding: Of 325 children enrolled in the Research Registry for Neonatal Lupus before October 2010, 57 (18%) died; 30% died in utero, 30% died during the neonatal period, 14% died between 1 and 6 months of age, and 26% died after 6 months of age.

Data Source: A retrospective analysis of data from a large U.S.-based cohort.

Disclosures: No disclosures.

ATLANTA — The overall case fatality rate in cardiac neonatal lupus is nearly 18%, according to a review of data from the Research Registry for Neonatal Lupus.

Of 325 children enrolled in the large U.S.-based registry before October 2010, 57 (18%) died; 30% died in utero, 30% died during the neonatal period, 14% died between 1 and 6 months of age, and 26% died after 6 months of age, said Dr. Peter M. Izmirly.

Of the deaths, 42 were cardiac related – most often a result of complications from cardiomyopathy, 6 were due to infectious complications, and 8 were a result of unknown causes. One pregnancy was terminated electively, said Dr. Izmirly of New York University, New York.

Of white children with cardiac neonatal lupus, 14% died, compared with 28% of minority children.

The study, which was conducted in an effort to update mortality data on cardiac neonatal lupus and to thereby improve evidence-based counseling of anti-Ro/La positive mothers whose babies are at increased risk of cardiac neonatal lupus, identified fetal and maternal risk factors for death in affected babies.

Significant fetal risk factors for death were associated hematologic hepatic neonatal lupus (present in 27% vs. 7% of deceased vs. living babies), earlier gestational age at detection (detection occurred at 21.8 vs. 23.4 weeks in deceased vs. living babies), delivery prior to 37 weeks' gestation (delivery occurred prior to 37 weeks in 69% vs. 42% of deceased vs. living babies), and earlier gestational week of delivery (delivery occurred at 34.2 weeks vs. 36.9 weeks in deceased vs. living babies), Dr. Izmirly said.

Fetal echocardiographic risk factors associated with mortality were lower ventricular rate nadir (rate was 50.2 vs. 53.6 in deceased vs. living babies), and the presence of endocardial fibroelastosis (which occurred in 30.25% vs. 4.3% of deceased vs. living babies), dilated cardiomyopathy (which occurred in 32.6% vs. 8.6% of deceased vs. living babies), hydrops (which occurred in 57.4% vs. 3.4% of deceased vs. living babies), and valvular disease (which occurred in18.2% vs. 4.8% of deceased vs. living babies).

Fetal echocardiographic factors not associated with mortality were ventricular rate detection, atrial septal defect, ventricular septal defect, and patent ductus arteriosus.

Only one maternal risk factor – a maternal diagnosis of systemic lupus erythematosus or Sjögren's syndrome – showed a trend toward significance in terms of risk for fetal death. Diagnosis occurred in 56% of women whose babies died, vs. 43% of those whose babies were living.

Recommended Reading

Methotrexate May Benefit Juvenile Scleroderma
MDedge Rheumatology
How to Deliver Bad News to Parents of Pediatric Patients
MDedge Rheumatology
Child's Fever, Limp May Be Septic Arthritis
MDedge Rheumatology
Lung Function Often Impaired in Juvenile Dermatomyositis
MDedge Rheumatology
JIA Remission May Be Elusive Despite Therapy
MDedge Rheumatology
Dental Splint Can Correct Facial Deformities in TMJ Arthritis
MDedge Rheumatology
Biologics May Pose Low Cancer Risk to Children With JIA
MDedge Rheumatology
Earlier Biologics Use in JIA Allows Less Steroids : More remissions are not the new rule with aggressive therapy, but other markers show improvement.
MDedge Rheumatology
Kids With Lupus Get Little Benefit From Statins
MDedge Rheumatology
Protocol Effective for Primary Angiitis of CNS
MDedge Rheumatology